![](images/graphics/blank.gif)
Chimeric antigen receptor T
-
Adoptive cell therapy has achieved great success in treating hematological malignancies. However, the production of chimeric antigen receptor T (CAR-T) cell therapy still faces various difficulties. Natural killer (NK)-92 is a continuously expandable cell line and provides a promising alternative for patient’s own immune cells.
12p
vishanshan
27-06-2024
2
1
Download
-
Nervous system toxicity (NST) is one of the most frequent and dangerous side effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for related tumors in most relapsed/refractory (r/r) hematologic malignancies. Current clinical trial data do not fully reflect the real-world situation. Therefore, this study evaluated the NST of CAR-T therapy using the FDA Adverse Event Reporting System (FAERS).
11p
vishanshan
27-06-2024
1
1
Download
-
Cancer immunotherapies including immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR) T-cell therapy have shown variable response rates in paediatric patients highlighting the need to establish robust biomarkers for patient selection.
24p
vicwell
29-02-2024
1
1
Download
-
Owing to non-responsiveness of a high number of patients to the common melanoma therapies, seeking novel approaches seem as an unmet requirement. Chimeric antigen receptor (CAR) T cells were initially employed against recurrent or refractory B cell malignancies.
9p
vileonardodavinci
23-12-2023
2
2
Download
-
Osteosarcoma (OS) mainly happens in children and youths. Surgery, radiotherapy and chemotherapy are the common therapies for osteosarcoma treatment but all their anti-tumor effects are limited.
12p
vileonardodavinci
23-12-2023
5
4
Download
-
Chimeric antigen receptor T (CAR-T) cell therapy, a new adoptive cell therapy, has been widely used to treat lymphoma patients. Immune checkpoint blockade may improve the cytotoxicity of CAR-T cells by reducing the failure of CAR-T cells and improving antitumor activity. It has shown promising efficacy.
9p
vialfrednobel
23-12-2023
5
3
Download
-
This study aims to assess the nutritional status of patients during the different phases of the Chimeric Antigen Receptor (CAR)-T cell therapy and to identify prominent risk factors of hypoalbuminemia in patients after CAR-T treatment. The clinical consequences of malnutrition in cancer patients have been highlighted by growing evidence from previous clinical studies.
8p
vialfrednobel
23-12-2023
5
3
Download
-
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/ refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of triple-class exposed RRMM. We report real-life experiences with the commercial use of ide-cel in RRMM patients.
10p
vischultz
20-10-2023
2
1
Download
-
To create chimeric antigen receptor (CAR) T cells and evaluate the effect on CD19+ B cells in animal models of acute lymphoblastic leukemia. Methods: An experimental research (In vitro and In vivo) was conducted at the Department of Pathophysiology, Military Medical University, from June 2019 to 2022.
11p
vipierre
29-09-2023
7
2
Download
-
Liệu pháp sử dụng tế bào T mang thụ thể kháng nguyên khảm CAR (Chimeric antigen receptors) là hướng mới tiềm năng trong điều trị bệnh bạch cầu cấp. Bài viết trình bày đánh giá ảnh hưởng của liệu pháp tế bào CAR-T phối hợp với kháng thể đơn dòng ức chế PD-1 đối với các chỉ số bạch cầu và nồng độ IL-6 trên thực nghiệm.
5p
vimurdoch
19-09-2023
3
2
Download
-
For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19 CAR-T cells may be ineffective due to anti-mouse single-chain variable fragment (scFv) antibody caused by mCD19 CAR.
8p
vikolindagrabar
27-07-2022
4
1
Download
-
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the adoptive immunotherapy of which is worth studying. CD133, a kind of cancer stem cell (CSC) antigen, together with glypican-3 (GPC3) has been proved to be highly expressed in HCC cells and both of them are used as targets to generate chimeric antigen receptor (CAR) T cells.
18p
vikolindagrabar
27-07-2022
1
1
Download
-
The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ Bcell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.
10p
vianrose2711
27-04-2021
9
1
Download
-
Asbestos is the main cause of MPM in industrialized countries. Even since asbestos is banned in most developed countries, the peak wave of MPM incidence is anticipated for the next years due to the long latency of asbestos induced MPM.
7p
vijisoo2711
30-09-2020
6
1
Download
-
Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers. Experimental therapy with CAR-engineered T cells has also shown promising results on solid tumors.
9p
vijennie2711
25-09-2020
20
1
Download
-
More favorable treatment against epithelial ovarian cancer (EOC) is urgently needed because of its insidious nature at an early stage and a low rate of five-year survival. The current primary treatment, extensive surgery combined with chemotherapy, exhibits limited benefits for improving prognosis.
13p
vidhaka2711
31-07-2020
13
1
Download
-
Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies.
13p
vimanila2711
25-06-2020
9
1
Download
-
Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
10p
viputrajaya2711
22-06-2020
9
0
Download
-
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma.
8p
viputrajaya2711
22-06-2020
14
0
Download
-
Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
17p
vikuala271
13-06-2020
14
1
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)